Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Bardoxolone Methyl in CTD-Associated Pulmonary Arterial Hypertension
2016-000196-24Phase 3Completed
- Sponsor
- Reata Pharmaceuticals
- Start
- Jun 2016
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Bardoxolone methyl with Placebo (2 arms). Primary endpoint: Change in six-minute walk distance at Week 24. Started Jun 2016; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2016-000196-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000196-24.